Tilray Brands (NASDAQ:TLRY) and InterCure (NASDAQ:INCR) Critical Comparison
by Mitch Edgeman · The Markets DailyInterCure (NASDAQ:INCR – Get Free Report) and Tilray Brands (NASDAQ:TLRY – Get Free Report) are both small-cap healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their risk, institutional ownership, earnings, dividends, valuation, analyst recommendations and profitability.
Profitability
This table compares InterCure and Tilray Brands’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| InterCure | N/A | N/A | N/A |
| Tilray Brands | -13.11% | -7.76% | -5.59% |
Analyst Ratings
This is a breakdown of current ratings and recommmendations for InterCure and Tilray Brands, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| InterCure | 1 | 0 | 0 | 0 | 1.00 |
| Tilray Brands | 1 | 3 | 2 | 1 | 2.43 |
Tilray Brands has a consensus target price of $7.00, suggesting a potential upside of 69.49%. Given Tilray Brands’ stronger consensus rating and higher probable upside, analysts plainly believe Tilray Brands is more favorable than InterCure.
Volatility & Risk
InterCure has a beta of 1.42, meaning that its share price is 42% more volatile than the S&P 500. Comparatively, Tilray Brands has a beta of 1.92, meaning that its share price is 92% more volatile than the S&P 500.
Valuation and Earnings
This table compares InterCure and Tilray Brands”s gross revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| InterCure | $78.47 million | 0.73 | -$10.37 million | $0.15 | 34.73 |
| Tilray Brands | $210.48 million | 2.67 | -$121.40 million | ($1.08) | -3.82 |
InterCure has higher earnings, but lower revenue than Tilray Brands. Tilray Brands is trading at a lower price-to-earnings ratio than InterCure, indicating that it is currently the more affordable of the two stocks.
Institutional and Insider Ownership
8.3% of InterCure shares are owned by institutional investors. Comparatively, 9.4% of Tilray Brands shares are owned by institutional investors. 0.2% of InterCure shares are owned by company insiders. Comparatively, 0.8% of Tilray Brands shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.
Summary
Tilray Brands beats InterCure on 9 of the 15 factors compared between the two stocks.
About InterCure
InterCure Ltd., together with its subsidiaries, engages in the research, cultivation, production, and distribution of pharmaceutical-grade cannabis and cannabis-based products for medical use in Israel and internationally. The company offers dried cannabis inflorescences and cannabis extract mixed with oil. It also invests in biomed sector. The company was incorporated in 1994 and is headquartered in Herzliya, Israel.
About Tilray Brands
Tilray, Inc. engages in the research, cultivation, processing, and distribution of medical cannabis. The company offers its products in Argentina, Australia, Canada, Chile, Croatia, Cyprus, the Czech Republic, Germany, New Zealand, and South Africa. Tilray, Inc. is headquartered in Canada.